Literature DB >> 34196305

Passive transfer of fibromyalgia symptoms from patients to mice.

Andreas Goebel1,2, Emerson Krock3, Clive Gentry4, Mathilde R Israel4, Alexandra Jurczak3, Carlos Morado Urbina3, Katalin Sandor3, Nisha Vastani4, Margot Maurer4, Ulku Cuhadar4, Serena Sensi2, Yuki Nomura3, Joana Menezes3, Azar Baharpoor3, Louisa Brieskorn3, Angelica Sandström5, Jeanette Tour5, Diana Kadetoff5,6, Lisbet Haglund7, Eva Kosek5,8, Stuart Bevan4, Camilla I Svensson3, David A Andersson4.   

Abstract

Fibromyalgia syndrome (FMS) is characterized by widespread pain and tenderness, and patients typically experience fatigue and emotional distress. The etiology and pathophysiology of fibromyalgia are not fully explained and there are no effective drug treatments. Here we show that IgG from FMS patients produced sensory hypersensitivity by sensitizing nociceptive neurons. Mice treated with IgG from FMS patients displayed increased sensitivity to noxious mechanical and cold stimulation, and nociceptive fibers in skin-nerve preparations from mice treated with FMS IgG displayed an increased responsiveness to cold and mechanical stimulation. These mice also displayed reduced locomotor activity, reduced paw grip strength, and a loss of intraepidermal innervation. In contrast, transfer of IgG-depleted serum from FMS patients or IgG from healthy control subjects had no effect. Patient IgG did not activate naive sensory neurons directly. IgG from FMS patients labeled satellite glial cells and neurons in vivo and in vitro, as well as myelinated fiber tracts and a small number of macrophages and endothelial cells in mouse dorsal root ganglia (DRG), but no cells in the spinal cord. Furthermore, FMS IgG bound to human DRG. Our results demonstrate that IgG from FMS patients produces painful sensory hypersensitivities by sensitizing peripheral nociceptive afferents and suggest that therapies reducing patient IgG titers may be effective for fibromyalgia.

Entities:  

Keywords:  Autoimmune diseases; Neurological disorders; Neuroscience; Pain

Year:  2021        PMID: 34196305     DOI: 10.1172/JCI144201

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  17 in total

1.  Prevalence of post-COVID-19 in patients with fibromyalgia: a comparative study with other inflammatory and autoimmune rheumatic diseases.

Authors:  Javier Rivera; Tamara Rodríguez; Marta Pallarés; Isabel Castrejón; Teresa González; Laura Vallejo-Slocker; Juan Molina-Collada; Fernando Montero; Anna Arias; Miguel A Vallejo; Jose M Alvaro-Gracia; Antonio Collado
Journal:  BMC Musculoskelet Disord       Date:  2022-05-19       Impact factor: 2.562

2.  Effects of Immunoglobulins G From Systemic Sclerosis Patients in Normal Dermal Fibroblasts: A Multi-Omics Study.

Authors:  Aurélien Chepy; Solange Vivier; Fabrice Bray; Camille Ternynck; Jean-Pascal Meneboo; Martin Figeac; Alexandre Filiot; Lucile Guilbert; Manel Jendoubi; Christian Rolando; David Launay; Sylvain Dubucquoi; Guillemette Marot; Vincent Sobanski
Journal:  Front Immunol       Date:  2022-06-29       Impact factor: 8.786

3.  The Pathobiology of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: The Case for Neuroglial Failure.

Authors:  Herbert Renz-Polster; Marie-Eve Tremblay; Dorothee Bienzle; Joachim E Fischer
Journal:  Front Cell Neurosci       Date:  2022-05-09       Impact factor: 6.147

4.  Sensory Perception Quotient Reveals Visual, Scent and Touch Sensory Hypersensitivity in People With Fibromyalgia Syndrome.

Authors:  Emma R Dorris; James Maccarthy; Ken Simpson; Geraldine M McCarthy
Journal:  Front Pain Res (Lausanne)       Date:  2022-07-05

5.  Unbiased immune profiling reveals a natural killer cell-peripheral nerve axis in fibromyalgia.

Authors:  Vivek Verma; Gillian L Drury; Marc Parisien; Ayşe N Özdağ Acarli; Tho-Alfakar Al-Aubodah; Anastasia Nijnik; Xia Wen; Nicol Tugarinov; Maria Verner; Richie Klares; Alexander Linton; Emerson Krock; Carlos E Morado Urbina; Bendik Winsvold; Lars G Fritsche; Egil A Fors; Ciriaco Piccirillo; Arkady Khoutorsky; Camilla I Svensson; Mary A Fitzcharles; Pablo M Ingelmo; Nicole F Bernard; Franck P Dupuy; Nurcan Üçeyler; Claudia Sommer; Irah L King; Carolina B Meloto; Luda Diatchenko
Journal:  Pain       Date:  2021-09-24       Impact factor: 7.926

Review 6.  Innovations and advances in modelling and measuring pain in animals.

Authors:  Katelyn E Sadler; Jeffrey S Mogil; Cheryl L Stucky
Journal:  Nat Rev Neurosci       Date:  2021-11-26       Impact factor: 38.755

7.  Distinct CholinomiR Blood Cell Signature as a Potential Modulator of the Cholinergic System in Women with Fibromyalgia Syndrome.

Authors:  Christoph Erbacher; Shani Vaknine; Gilli Moshitzky; Sebastian Lobentanzer; Lina Eisenberg; Dimitar Evdokimov; Claudia Sommer; David S Greenberg; Hermona Soreq; Nurcan Üçeyler
Journal:  Cells       Date:  2022-04-09       Impact factor: 7.666

Review 8.  The autonomic aspects of the post-COVID19 syndrome.

Authors:  Arad Dotan; Paula David; Dana Arnheim; Yehuda Shoenfeld
Journal:  Autoimmun Rev       Date:  2022-02-16       Impact factor: 17.390

9.  Sex-Specific B Cell and Anti-Myelin Autoantibody Response After Peripheral Nerve Injury.

Authors:  Hee Jong Lee; Albert G Remacle; Swathi K Hullugundi; Jennifer Dolkas; Jake B Leung; Andrei V Chernov; Tony L Yaksh; Alex Y Strongin; Veronica I Shubayev
Journal:  Front Cell Neurosci       Date:  2022-04-14       Impact factor: 6.147

10.  Chronic Pain Treatment and Digital Health Era-An Opinion.

Authors:  V Rejula; J Anitha; R V Belfin; J Dinesh Peter
Journal:  Front Public Health       Date:  2021-12-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.